BR112023004214A2 - Métodos de tratamento de doenças ou condições mediadas por pde iv - Google Patents
Métodos de tratamento de doenças ou condições mediadas por pde ivInfo
- Publication number
- BR112023004214A2 BR112023004214A2 BR112023004214A BR112023004214A BR112023004214A2 BR 112023004214 A2 BR112023004214 A2 BR 112023004214A2 BR 112023004214 A BR112023004214 A BR 112023004214A BR 112023004214 A BR112023004214 A BR 112023004214A BR 112023004214 A2 BR112023004214 A2 BR 112023004214A2
- Authority
- BR
- Brazil
- Prior art keywords
- diseases
- pde
- methods
- treatment
- conditions mediated
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000001404 mediated effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
MÉTODOS DE TRATAMENTO DE DOENÇAS U CONDIÇÕES MEDIADAS POR PDE IV. presente invenção refere-se a métodos e composições para o tratamento de doenças ou condições mediadas por PDE IV, incluindo doenças ou condições inflamatórias, utilizando um composto da Fórmula (I) ou um sal farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076774P | 2020-09-10 | 2020-09-10 | |
| PCT/US2021/049870 WO2022056265A1 (en) | 2020-09-10 | 2021-09-10 | Methods of treating pde iv-mediated diseases or conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023004214A2 true BR112023004214A2 (pt) | 2023-04-11 |
Family
ID=78080507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023004214A BR112023004214A2 (pt) | 2020-09-10 | 2021-09-10 | Métodos de tratamento de doenças ou condições mediadas por pde iv |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230364100A1 (pt) |
| EP (1) | EP4210674A1 (pt) |
| JP (1) | JP2023541261A (pt) |
| KR (1) | KR20230066350A (pt) |
| CN (1) | CN116507336A (pt) |
| AU (1) | AU2021338837A1 (pt) |
| BR (1) | BR112023004214A2 (pt) |
| CA (1) | CA3191177A1 (pt) |
| CL (1) | CL2023000648A1 (pt) |
| IL (1) | IL300628A (pt) |
| MX (1) | MX2023002539A (pt) |
| WO (1) | WO2022056265A1 (pt) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004024728A2 (en) | 2002-09-16 | 2004-03-25 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
| KR20180102590A (ko) | 2015-12-24 | 2018-09-17 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Cftr 조절제 및 이의 사용방법 |
| CN111629730A (zh) * | 2017-08-24 | 2020-09-04 | 加利福尼亚大学董事会 | 眼部药物组合物 |
-
2021
- 2021-09-10 MX MX2023002539A patent/MX2023002539A/es unknown
- 2021-09-10 US US18/044,805 patent/US20230364100A1/en active Pending
- 2021-09-10 BR BR112023004214A patent/BR112023004214A2/pt unknown
- 2021-09-10 KR KR1020237008089A patent/KR20230066350A/ko unknown
- 2021-09-10 CA CA3191177A patent/CA3191177A1/en active Pending
- 2021-09-10 JP JP2023515808A patent/JP2023541261A/ja active Pending
- 2021-09-10 AU AU2021338837A patent/AU2021338837A1/en active Pending
- 2021-09-10 EP EP21787173.0A patent/EP4210674A1/en active Pending
- 2021-09-10 WO PCT/US2021/049870 patent/WO2022056265A1/en active Application Filing
- 2021-09-10 CN CN202180062221.XA patent/CN116507336A/zh active Pending
- 2021-09-10 IL IL300628A patent/IL300628A/en unknown
-
2023
- 2023-03-07 CL CL2023000648A patent/CL2023000648A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023000648A1 (es) | 2023-10-13 |
| KR20230066350A (ko) | 2023-05-15 |
| MX2023002539A (es) | 2023-03-14 |
| IL300628A (en) | 2023-04-01 |
| JP2023541261A (ja) | 2023-09-29 |
| WO2022056265A1 (en) | 2022-03-17 |
| CN116507336A (zh) | 2023-07-28 |
| CA3191177A1 (en) | 2022-03-17 |
| US20230364100A1 (en) | 2023-11-16 |
| EP4210674A1 (en) | 2023-07-19 |
| AU2021338837A1 (en) | 2023-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
| CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
| BR112022010383A2 (pt) | Compostos tricíclicos substituídos | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BR112018015413A2 (pt) | inibidores de indoleamina-2,3-dioxigenase (ido) | |
| CO6660497A2 (es) | Derivados del ácido nft-2-ilacético para tratar el sida | |
| NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
| CO2021005532A2 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| BR112022024597A2 (pt) | Compostos de 4-oxo-3,4-di-hidroquinazolinona para o tratamento de doenças e distúrbios associados com braf | |
| BR112018069147A2 (pt) | composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh | |
| BR112022010082A2 (pt) | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica | |
| MX2022015531A (es) | Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo. | |
| BR112018016349A2 (pt) | métodos para tratamento e profilaxia de hiv e aids | |
| EA202192433A1 (ru) | Соединения, полезные в терапии вич | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| BR112017000132A2 (pt) | composto, composição farmacêutica e método de tratamento ou prevenção de uma doença responsiva à inibição da atividade de pi3k | |
| BR112022020814A2 (pt) | Métodos para tratamento de síndrome de liberação de citocina | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| BR112022005627A2 (pt) | Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica e uso de um composto | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| BR112021018335A2 (pt) | Derivados de benzodiazepina como inibidores de rsv | |
| BR112023021161A2 (pt) | Derivados de ureia de piperidina como inibidores de epóxido hidrolase solúveis |